MTOR and neoplasm: Previous studies have demonstrated that miR-664b-3p directly targets Rheb, a key regulator of the Rheb/mTOR/c-MYC signalling pathway, which promotes glycolysis and tumour growth in osteosarcoma (OS) cells [43].